Who Paid My Doc
Mark Scarupa
Allergy & Immunology Wheaton, MD Medical Doctor
NPI 1659303774 CMS profile 165101
11002 Veirs Mill Rd, 414, Wheaton, MD 20902
General payments
$507,735
Research payments
$2,408
Ownership & investment interest
$36,238
Research they led as principal investigator
$682,450
Through program year 2025, Mark Scarupa of Wheaton, MD is reported in the CMS Open Payments database as having received $507,735 across 1,227 general payments and $2,408 in research payments paid to them. Separately, studies naming them as principal investigator received $682,450 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $36,238 across 2 holdings.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 98th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
11 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $153,254 | 279 | |
| 2024 | General | $125,738 | 229 | |
| 2024 | Research | $1,908 | 9 | |
| 2023 | General | $53,478 | 183 | |
| 2022 | General | $20,798 | 147 | |
| 2022 | Research | $500 | 1 | |
| 2021 | General | $35,806 | 106 | |
| 2020 | General | $16,312 | 99 | |
| 2019 | General | $102,350 | 184 | |
| 2025 | Ownership | $18,119 | 1 | |
| 2024 | Ownership | $18,119 | 1 |
Beside peers
- Mark Scarupa
- Allergy & Immunology median
- Middle half of Allergy & Immunology
- National median
In program year 2025, general payments to Mark Scarupa were reported at $153,254. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.
Show as a table
| Year | Mark Scarupa | Allergy & Immunology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $102,350 | $594 | $163–$1,512 | $163 |
| 2020 | $16,312 | $426 | $106–$1,233 | $114 |
| 2021 | $35,806 | $638 | $157–$1,708 | $132 |
| 2022 | $20,798 | $790 | $205–$1,961 | $149 |
| 2023 | $53,478 | $852 | $220–$2,147 | $160 |
| 2024 | $125,738 | $865 | $203–$2,267 | $164 |
| 2025 | $153,254 | $1,140 | $272–$2,892 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 11 drugsPart D claims
349
Drug cost
$410,968
Branded share of claims
42.1%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Takhzyro Lanadelumab-Flyo | Brand | 11 | $331,580 | |
| Dupixent Syringe Dupilumab | Brand | 11 | $48,486 | |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 18 | $14,885 | |
| Azelastine-Fluticasone Azelastine/Fluticasone | Brand | 34 | $4,409 | |
| Symbicort Budesonide/Formoterol Fumarate | Brand | 12 | $2,749 | |
| Ipratropium Bromide | Generic | 85 | $2,656 | |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | Brand | 15 | $2,285 | |
| Montelukast Sodium | Generic | 61 | $1,686 | |
| Albuterol Sulfate Hfa Albuterol Sulfate | Brand | 46 | $1,375 | |
| Azelastine Hcl | Generic | 21 | $748 |
The 10 drugs with the highest cost, of 11 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 65 billing codesPaid by Medicare
$1,164,828
Medicare patients
505
Services billed
42,438
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 60% | |
| Arthritis | 51% | |
| Osteoporosis | 27% | |
| Ischemic heart disease | 20% | |
| Diabetes | 19% | |
| Depression | 18% | |
| Cancer | 16% | |
| Chronic kidney disease | 13% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, immune globulin (bivigam), 500 mg J1556 | Office | 22 | 6,030 | $349,953 |
| Injection, omalizumab, 5 mg J2357 | Office | 23 | 7,500 | $223,626 |
| Vaccine for pneumococcal polysaccharide for injection beneath the skin or into muscle, patient 2 years or older 90732 | Office | 11 | 11 | $1,439 |
| Vaccine for influenza for injection into muscle 90662 | Office | 18 | 18 | $1,340 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
First 5 of 29 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| XOLAIR |
|
$51,724 | — | 7,500 |
| AYVAKIT |
|
$27,722 | — | — |
| Xembify |
|
$13,113 | — | — |
| TEZSPIRE |
|
$10,844 | — | — |
| OPZELURA |
|
$7,398 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See more in the dashboard: 25 with a free account, all 29 with PatronRecords
1,237 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Allergy & Immunology in Maryland
Manav Singla
Allergy & Immunology · White Marsh, MD
Sudhir Sekhsaria
Allergy & Immunology · Rockville, MD
Nasim Reedy
Allergy & Immunology · Gaithersburg, MD
Kristin Sokol
Allergy & Immunology · Rockville, MD
Rachel Schreiber
Allergy & Immunology · Rockville, MD
Matthew Mardiney
Allergy & Immunology · Bel Air, MD
Related records
Allergy & Immunology in Maryland
Practitioners in the same specialty and state, ranked by reported value.
All Allergy & Immunology
Everyone recorded under this specialty, nationwide.
Doctors in Maryland
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.